More psoriasis patients achieve efficacy when they receive continuous treatment with Humira (adalimumab) compared to patients who interrupt their therapy, according to data presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris.
The details can be read here.
No comments:
Post a Comment